Immunocore Holdings plc APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Immunocore Holdings plc (IMCR) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $9.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-06
- Immunocore Holdings plc apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $9.40M, a 7.40% decline year-over-year.
- Immunocore Holdings plc apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $6.30M, a 33.77% decline year-over-year.
- Immunocore Holdings plc apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $9.79M, a 50.35% increase year-over-year.
- Immunocore Holdings plc apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $10.16M, a 1.78% increase year-over-year.
- Immunocore Holdings plc apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $37.78M, a 10.48% increase from fiscal 2024.
- Immunocore Holdings plc apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $34.20M, a 5.32% increase from fiscal 2023.
- Immunocore Holdings plc apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $32.47M, a 1.27% decline from fiscal 2022.
- Immunocore Holdings plc apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $32.89M, a 32.74% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.40M 10-Q · filed 2026-08-06 | $15.71M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $6.30M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $37.78M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $9.79M 10-Q · filed 2025-11-06 | $19.94M derived: sum of 2 quarters · filed 2026-08-06 | $29.46M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $10.16M 10-Q · filed 2026-08-06 | $19.67M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $9.52M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $34.20M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $6.51M 10-Q · filed 2025-11-06 | $16.49M derived: sum of 2 quarters · filed 2025-11-06 | $25.50M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $9.98M 10-Q · filed 2025-11-06 | $19.00M 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | $9.02M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $32.47M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $8.20M 10-Q · filed 2024-11-06 | $17.02M derived: sum of 2 quarters · filed 2024-11-06 | $25.28M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $8.82M 10-Q · filed 2024-11-06 | $17.08M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $8.26M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $32.89M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $48.89M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |